Market Cap 1.97B
Revenue (ttm) 727.33M
Net Income (ttm) -108.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -14.85%
Debt to Equity Ratio 0.00
Volume 2,179,000
Avg Vol 2,639,686
Day's Range N/A - N/A
Shares Out 130.21M
Stochastic %K 91%
Beta 1.74
Analysts Strong Sell
Price Target $15.05

Company Profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the pr...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 239 768 0600
Fax: 239 690 4237
Address:
9490 NeoGenomics Way, Fort Myers, United States
MorganHoratio
MorganHoratio Jul. 2 at 9:57 PM
One of the strongest sectors outside of AI right now is Biotech. Oncology $PSNL Personalis $GH Guardant Health $NEO NeoGenomics $INCY Incyte Non-AI capital flows heavily into precision oncology and screening tech! Smart money triggers tactical limit entries atop long-term FIB volume floors, lock-floating diagnostic monopolies. Early-screening king GH leads the breakout on explosive Shield revenue and full-year guidance upgrades, while path-leader NEO secures NGS pathology profitability and PSNL firms up technical entries. Flanking them, biopharma vanguard INCY hardens its valuation ceiling following key European Opzelura backing. Clinical execution means nothing without scalable adoption and margins. Facing this oncology rotation, are you buying the FIB support floors or holding defensive cash? Drop your execution playbook below!
1 · Reply
bmwbuzzz
bmwbuzzz Jul. 2 at 5:33 PM
$NEO MEH shill post below Purely a coattails (Mikey come lately) call
0 · Reply
MikeCaymanTrades
MikeCaymanTrades Jul. 2 at 3:56 AM
$NEO Signal Update Today's recommendation from our system is to STAY LONG. The previous BUY signal was issued on 06/22/2026, 9 days ago, when the stock price was 11.20. Since then, NEO has risen by +33.66%. Youtube call 7 days ago boom!
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 1 at 12:18 PM
@Lambrusco what’s good brotha $HLYK Where are you getting 4x average volume boiii? HLYK only traded around 4k shares. That’s nowhere near enough volume to draw conclusions about institutional selling or broad market sentiment. On an illiquid OTC stock, a small sell order can move the price. I’d focus more on execution, adoption of the new AI platform, and future revenue than one low-volume trading day. Btw Under 2M float = very little supply. If buying volume and positive catalysts arrive at the same time, the lack of available shares can fuel sharp price moves. Low float isn’t a catalyst by itself but paired with strong execution and demand, it can make things interesting. 🚀 $NEO $TDOC $AI
1 · Reply
carminefox
carminefox Jun. 26 at 12:45 AM
$NEO someone knows something! 👀
0 · Reply
bmwbuzzz
bmwbuzzz Jun. 25 at 8:47 PM
$NEO Took a couple grand (shares) off the table...but, really psyched about the recent price movement.
0 · Reply
MikeCaymanTrades
MikeCaymanTrades Jun. 25 at 2:45 AM
https://www.youtube.com/watch?v=Skcq-2Z_f0M&t=4s $NEO
0 · Reply
topstockalerts
topstockalerts Jun. 24 at 8:44 PM
$NEO the trend has a very natural feel to it.
0 · Reply
msufans
msufans Jun. 24 at 6:39 PM
$NEO possibility of buyout?
0 · Reply
AnyMonkey
AnyMonkey Jun. 24 at 5:35 PM
$NEO wonder whats driving todays 10% gain…
1 · Reply
Latest News on NEO
NeoGenomics appoints Starrett to its Board of Directors

2026-06-25T11:10:49.000Z - 9 days ago

NeoGenomics appoints Starrett to its Board of Directors


NeoGenomics to Present New Research at ASCO Annual Meeting 2026

May 26, 2026, 7:05 AM EDT - 5 weeks ago

NeoGenomics to Present New Research at ASCO Annual Meeting 2026


NeoGenomics Transcript: AGM 2026

May 21, 2026, 10:00 AM EDT - 6 weeks ago

NeoGenomics Transcript: AGM 2026


NeoGenomics to Participate in Upcoming Investor Conferences

May 15, 2026, 9:05 AM EDT - 7 weeks ago

NeoGenomics to Participate in Upcoming Investor Conferences


NeoGenomics price target lowered to $11 from $13 at BofA

2026-04-29T16:45:29.000Z - 2 months ago

NeoGenomics price target lowered to $11 from $13 at BofA


NeoGenomics price target raised to $14 from $13 at TD Cowen

2026-04-29T13:42:05.000Z - 2 months ago

NeoGenomics price target raised to $14 from $13 at TD Cowen


NeoGenomics upgraded to Buy from Hold at Benchmark

2026-04-29T10:26:48.000Z - 2 months ago

NeoGenomics upgraded to Buy from Hold at Benchmark


NeoGenomics reports Q1 adjusted EPS 1c, consensus 0c

2026-04-28T21:39:08.000Z - 2 months ago

NeoGenomics reports Q1 adjusted EPS 1c, consensus 0c


NeoGenomics Earnings Call Transcript: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 2 months ago

NeoGenomics Earnings Call Transcript: Q1 2026


NeoGenomics Earnings release: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 2 months ago

NeoGenomics Earnings release: Q1 2026


NeoGenomics Slides: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 2 months ago

NeoGenomics Slides: Q1 2026


NeoGenomics Quarterly report: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 2 months ago

NeoGenomics Quarterly report: Q1 2026


NeoGenomics Reports First Quarter 2026 Results

Apr 28, 2026, 4:05 PM EDT - 2 months ago

NeoGenomics Reports First Quarter 2026 Results


NeoGenomics expands access to full oncology testing portfolio

2026-04-23T11:26:56.000Z - 2 months ago

NeoGenomics expands access to full oncology testing portfolio


NeoGenomics Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 3 months ago

NeoGenomics Proxy statement: Proxy filing


NeoGenomics Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 3 months ago

NeoGenomics Proxy statement: Proxy filing


NeoGenomics PanTracer LBx test receives Medicare coverage

2026-03-16T11:28:54.000Z - 3 months ago

NeoGenomics PanTracer LBx test receives Medicare coverage


NeoGenomics Slides: Investor presentation

Mar 10, 2026, 3:00 PM EDT - 4 months ago

NeoGenomics Slides: Investor presentation


NeoGenomics Earnings Call Transcript: Q4 2025

Feb 17, 2026, 8:30 AM EST - 4 months ago

NeoGenomics Earnings Call Transcript: Q4 2025


NeoGenomics Annual report: Q4 2025

Feb 17, 2026, 8:30 AM EST - 4 months ago

NeoGenomics Annual report: Q4 2025


NeoGenomics Earnings release: Q4 2025

Feb 17, 2026, 8:30 AM EST - 4 months ago

NeoGenomics Earnings release: Q4 2025


NeoGenomics Slides: Q4 2025

Feb 17, 2026, 8:30 AM EST - 4 months ago

NeoGenomics Slides: Q4 2025


NeoGenomics sees FY26 adjusted EPS 16c-21c, consensus 19c

2026-02-17T12:45:49.000Z - 4 months ago

NeoGenomics sees FY26 adjusted EPS 16c-21c, consensus 19c


NeoGenomics reports Q4 adjusted EPS 6c, consensus 4c

2026-02-17T12:40:53.000Z - 4 months ago

NeoGenomics reports Q4 adjusted EPS 6c, consensus 4c


NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

Feb 17, 2026, 7:05 AM EST - 4 months ago

NeoGenomics Reports Fourth Quarter and Full Year 2025 Results


NeoGenomics to Present New ctDNA Research at SABCS 2025

Dec 10, 2025, 7:05 AM EST - 7 months ago

NeoGenomics to Present New ctDNA Research at SABCS 2025


NeoGenomics Transcript: Stephens Annual Investment Conference

Nov 19, 2025, 2:00 PM EST - 8 months ago

NeoGenomics Transcript: Stephens Annual Investment Conference


NeoGenomics Earnings Call Transcript: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 8 months ago

NeoGenomics Earnings Call Transcript: Q3 2025


NeoGenomics Quarterly report: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 8 months ago

NeoGenomics Quarterly report: Q3 2025


NeoGenomics Earnings release: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 8 months ago

NeoGenomics Earnings release: Q3 2025


NeoGenomics Slides: Q3 2025

Oct 28, 2025, 8:30 AM EDT - 8 months ago

NeoGenomics Slides: Q3 2025


NeoGenomics Reports Third Quarter 2025 Results

Oct 28, 2025, 7:05 AM EDT - 8 months ago

NeoGenomics Reports Third Quarter 2025 Results


NeoGenomics Earnings Call Transcript: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Earnings Call Transcript: Q2 2025


NeoGenomics Quarterly report: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Quarterly report: Q2 2025


NeoGenomics Earnings release: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Earnings release: Q2 2025


NeoGenomics Slides: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Slides: Q2 2025


NeoGenomics Reports Second Quarter 2025 Results

Jul 29, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Reports Second Quarter 2025 Results


NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

Jun 24, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Appoints Dr. Marjorie Green to Board of Directors


NeoGenomics Pays Off 1.25% Convertible Senior Notes

May 1, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Pays Off 1.25% Convertible Senior Notes


NeoGenomics Earnings Call Transcript: Q1 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Earnings Call Transcript: Q1 2025


NeoGenomics Quarterly report: Q1 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Quarterly report: Q1 2025


NeoGenomics Earnings release: Q1 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Earnings release: Q1 2025


NeoGenomics Slides: Q1 2025

Apr 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Slides: Q1 2025


NeoGenomics Reports First Quarter 2025 Results

Apr 29, 2025, 7:30 AM EDT - 1 year ago

NeoGenomics Reports First Quarter 2025 Results


NeoGenomics Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

NeoGenomics Proxy statement: Proxy Filing


NeoGenomics Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

NeoGenomics Proxy statement: Proxy Filing


NeoGenomics Completes Acquisition of Pathline

Apr 7, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Completes Acquisition of Pathline


NeoGenomics Earnings Call Transcript: Q4 2024

Feb 18, 2025, 8:30 AM EST - 1 year ago

NeoGenomics Earnings Call Transcript: Q4 2024


NeoGenomics Annual report: Q4 2024

Feb 18, 2025, 8:30 AM EST - 1 year ago

NeoGenomics Annual report: Q4 2024


NeoGenomics Earnings release: Q4 2024

Feb 18, 2025, 8:30 AM EST - 1 year ago

NeoGenomics Earnings release: Q4 2024


NeoGenomics Slides: Q4 2024

Feb 18, 2025, 8:30 AM EST - 1 year ago

NeoGenomics Slides: Q4 2024


NeoGenomics Reports Fourth Quarter and Full Year 2024 Results

Feb 18, 2025, 7:05 AM EST - 1 year ago

NeoGenomics Reports Fourth Quarter and Full Year 2024 Results


MorganHoratio
MorganHoratio Jul. 2 at 9:57 PM
One of the strongest sectors outside of AI right now is Biotech. Oncology $PSNL Personalis $GH Guardant Health $NEO NeoGenomics $INCY Incyte Non-AI capital flows heavily into precision oncology and screening tech! Smart money triggers tactical limit entries atop long-term FIB volume floors, lock-floating diagnostic monopolies. Early-screening king GH leads the breakout on explosive Shield revenue and full-year guidance upgrades, while path-leader NEO secures NGS pathology profitability and PSNL firms up technical entries. Flanking them, biopharma vanguard INCY hardens its valuation ceiling following key European Opzelura backing. Clinical execution means nothing without scalable adoption and margins. Facing this oncology rotation, are you buying the FIB support floors or holding defensive cash? Drop your execution playbook below!
1 · Reply
bmwbuzzz
bmwbuzzz Jul. 2 at 5:33 PM
$NEO MEH shill post below Purely a coattails (Mikey come lately) call
0 · Reply
MikeCaymanTrades
MikeCaymanTrades Jul. 2 at 3:56 AM
$NEO Signal Update Today's recommendation from our system is to STAY LONG. The previous BUY signal was issued on 06/22/2026, 9 days ago, when the stock price was 11.20. Since then, NEO has risen by +33.66%. Youtube call 7 days ago boom!
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 1 at 12:18 PM
@Lambrusco what’s good brotha $HLYK Where are you getting 4x average volume boiii? HLYK only traded around 4k shares. That’s nowhere near enough volume to draw conclusions about institutional selling or broad market sentiment. On an illiquid OTC stock, a small sell order can move the price. I’d focus more on execution, adoption of the new AI platform, and future revenue than one low-volume trading day. Btw Under 2M float = very little supply. If buying volume and positive catalysts arrive at the same time, the lack of available shares can fuel sharp price moves. Low float isn’t a catalyst by itself but paired with strong execution and demand, it can make things interesting. 🚀 $NEO $TDOC $AI
1 · Reply
carminefox
carminefox Jun. 26 at 12:45 AM
$NEO someone knows something! 👀
0 · Reply
bmwbuzzz
bmwbuzzz Jun. 25 at 8:47 PM
$NEO Took a couple grand (shares) off the table...but, really psyched about the recent price movement.
0 · Reply
MikeCaymanTrades
MikeCaymanTrades Jun. 25 at 2:45 AM
https://www.youtube.com/watch?v=Skcq-2Z_f0M&t=4s $NEO
0 · Reply
topstockalerts
topstockalerts Jun. 24 at 8:44 PM
$NEO the trend has a very natural feel to it.
0 · Reply
msufans
msufans Jun. 24 at 6:39 PM
$NEO possibility of buyout?
0 · Reply
AnyMonkey
AnyMonkey Jun. 24 at 5:35 PM
$NEO wonder whats driving todays 10% gain…
1 · Reply
bmwbuzzz
bmwbuzzz Jun. 24 at 3:01 PM
$NEO and so it goes!
0 · Reply
Doozio
Doozio Jun. 21 at 12:10 AM
ONTO 🐒🍌🧠⏰♾️ $NEO
0 · Reply
Kat_Harington
Kat_Harington Jun. 18 at 10:33 PM
0 · Reply
G101SPM
G101SPM Jun. 17 at 12:41 PM
#DILUTION Adaptive Biotechnologies ($ADPT) prices upsized offering of $300 mln of 0% convertible senior notes due 2031 (from $250 mln); Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement NeoGenomics ($NEO) prices offering of $275 mln of 0.75% convertible senior notes due 2032 Pattern Group ($PTRN) prices offering of 8.0 mln shares of common stock at $19.00 per share SOPHiA GENETICS ($SOPH) prices offering of 10,526,000 ordinary shares at $4.75 per ordinary share
0 · Reply
bmwbuzzz
bmwbuzzz Jun. 16 at 2:36 PM
$NEO Re: convertible note offering. Yes, a convertible note offering is inherently dilutive. While it delays dilution today by acting as debt, it creates a "deferred equity dilution". When the note later converts into shares, it increases the total outstanding share count, thereby reducing the proportional ownership of existing shareholders. HOWEVER - as a "loan", it can also be closed using cash. If NEO uses the $$$ to further grow revenue/profits, this can result in a non-dilutive event. Market is reacting negatively, but correcting back up appropriately.
0 · Reply
Kat_Harington
Kat_Harington Jun. 16 at 1:40 PM
$NEO someone correct me if I’m wrong here, but this is down because of the 275 million dollar convertible note offering? Effectively diluting our shares?
1 · Reply
GordoHLYK13
GordoHLYK13 Jun. 13 at 2:18 PM
$HLYK $NEO $AMZN Been holding $HLYK since 2019. Started with over 800k shares pre-split under $.05 — now sitting around 8k shares with a much higher average near $5.50 after the reverse split. Yeah, the dilution and cash concerns are real, but I’m still holding because this isn’t just a tiny clinic company anymore. HLYK is building a healthcare AI/data ecosystem with telemedicine, patient integration, ARi AI, and expanding partnerships. The market only sees the struggles. I see a micro-cap trying to evolve into a scalable digital healthcare platform. If management secures funding and finally monetizes the tech, the upside from these levels could be enormous due to the tiny market cap. High risk, yes — that’s why I’m here Despite the dilution, reverse split, and survival concerns, the article confirms $HLYK is still fighting to transform itself into an AI-driven digital healthcare platform — and if they execute, the upside from these beaten-down levels could be enormous.
1 · Reply
bmwbuzzz
bmwbuzzz Jun. 4 at 2:09 PM
$NEO Make up your mind, NEO! Appreciate the bounce back...but what is driving the 5%+ swings?!?
1 · Reply
bmwbuzzz
bmwbuzzz Jun. 1 at 4:26 AM
$NEO odd that the sentiment is bearish. Guessing its from the low volume of posts.
0 · Reply
DriveForShow
DriveForShow May. 28 at 8:06 PM
$NEO $10 was not on my bingo card this week. See if this holds. Not holding breath
0 · Reply
GordoHLYK13
GordoHLYK13 May. 27 at 3:05 PM
$NEO @GambleLifeAway
0 · Reply
GordoHLYK13
GordoHLYK13 May. 27 at 3:04 PM
$NEO @GambleLifeAway Boom
0 · Reply